Volume | 189,872 |
|
|||||
News | - | ||||||
Day High | 9.08 | Low High |
|||||
Day Low | 8.41 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
8.52 | 8.41 | 9.08 | 8.98 | 8.54 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,141 | 189,872 | US$ 8.80 | US$ 1,671,066 | - | 1.81 - 15.05 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:01:01 | formt | 1,034 | US$ 8.97 | USD |
Solid Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
339.06M | 37.76M | - | 0 | -96.02M | -2.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Solid Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.13 | 9.61 | 7.95 | 8.82 | 223,248 | -0.15 | -1.64% |
1 Month | 13.47 | 13.47 | 7.95 | 10.50 | 189,880 | -4.49 | -33.33% |
3 Months | 6.73 | 15.05 | 6.54 | 11.16 | 254,985 | 2.25 | 33.43% |
6 Months | 2.04 | 15.05 | 1.81 | 6.50 | 458,853 | 6.94 | 340.20% |
1 Year | 4.55 | 15.05 | 1.81 | 6.39 | 239,390 | 4.43 | 97.36% |
3 Years | 77.25 | 81.90 | 1.81 | 25.60 | 549,635 | -68.27 | -88.38% |
5 Years | 141.00 | 203.70 | 1.81 | 55.11 | 846,126 | -132.02 | -93.63% |
Solid Biosciences Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |